| Details: |
Cocrystal systems are increasingly being considered for many industrial applications including explosives, semiconductors, pigments, and pharmaceuticals. Recently, FDA approved Entresto™ which contains valsartan:sacubitril cocrystal. In the last decade there have been few reports about the development of innovative technologies for the manufacture and formulation of cocrystals. To obtain a successful pharmaceutical cocrystal product, it is crucial to understand cocrystal behavior during manufacturing, storage, and administration as cocrystals can undergo different types of structural changes. Notably, solvent-free thermal or shear force mediated transformations that include stoichiometric conversion have been reported and it was ascribed to the energy difference between the cocrystal and the individual components. The stability issue in formulations is further complicated due to the presence of additives. The presentation will focus research at the Centre for Pharmaceutical Engineering Science (CPES) in the area innovation in processing and formulation of co-crystals. |